Walter

OBSI announces new board members

Retrieved on: 
Friday, March 1, 2024

TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- The Board of Directors for the Ombudsman for Banking Services and Investments (OBSI) is pleased to announce four appointments to the board:

Key Points: 
  • TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- The Board of Directors for the Ombudsman for Banking Services and Investments (OBSI) is pleased to announce four appointments to the board:
    Mary Condon has joined the board as a Consumer Interest Director.
  • Previously, she was a board member of the Capital Markets Authority Implementation Organization, and Commissioner and board member of the Ontario Securities Commission (OSC), where she was also a Vice-Chair.
  • All directors have a fiduciary duty to OBSI and do not advocate for or represent any outside interest while engaged in OBSI governance.
  • If a consumer has a complaint against an OBSI participating bank or investment firm that they are not able to resolve with the bank or firm, OBSI will investigate at no cost to the consumer.

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

Retrieved on: 
Friday, February 23, 2024

“These additional analyses of real-world use of ORLADEYO show that any person living with HAE has the potential to experience a rapid, substantial and sustained reduction in their monthly attack rate with ORLADEYO.

Key Points: 
  • “These additional analyses of real-world use of ORLADEYO show that any person living with HAE has the potential to experience a rapid, substantial and sustained reduction in their monthly attack rate with ORLADEYO.
  • These analyses present the overall attack rate progression and attack rate progression stratified by severity (i.e., number of attacks at baseline), prior prophylaxis and C1-INH level and function.
  • These findings further demonstrate that ORLADEYO can help maintain disease control in patients with lower baseline attack rates and further reduce attack rates in patients with more active disease.
  • Berotralstat Prophylaxis Reduces HAE Attack Rates Regardless of Baseline Attacks: Real-World Outcomes; Poster #012; Friday, February 23, 3:15-4:15 p.m.

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Retrieved on: 
Thursday, February 22, 2024

CHAPTER-1 is a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and type 2 (HAE-1/2).

Key Points: 
  • CHAPTER-1 is a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and type 2 (HAE-1/2).
  • 34 participants were treated with double-blinded study drug (placebo or deucrictibant, 20 or 40 mg/day) for 12 weeks of treatment.
  • “These data validate the mechanism of deucrictibant to provide early and sustained protection from HAE attacks.
  • By better understanding and addressing these factors, we aspire to make our commitment to ‘pioneering science for patient choice’ a reality.”

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Retrieved on: 
Tuesday, February 20, 2024

DBV is sponsoring a non-CME Product Theater titled “Importance of Early Intervention for Peanut Allergy.” Professors Hugh Sampson, M.D.

Key Points: 
  • DBV is sponsoring a non-CME Product Theater titled “Importance of Early Intervention for Peanut Allergy.” Professors Hugh Sampson, M.D.
  • DBV will host a booth (#567) in the AAAAI exhibit hall where attendees can learn more about epicutaneous immunotherapy with Viaskin, including our ongoing clinical trials in peanut-allergic children.
  • Chief Medical Officer at DBV Technologies.
  • “DBV, is committed to generating robust, long-term safety data with Viaskin Peanut to aid in future shared decision-making.

AST SpaceMobile Announces Participation in Upcoming Conferences

Retrieved on: 
Tuesday, February 20, 2024

AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, today announced participation in the following upcoming industry and investor conferences:

Key Points: 
  • AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, today announced participation in the following upcoming industry and investor conferences:
    Mobile World Congress, taking place on Monday, February 26 to Thursday, February 29 at the Fira Gran Via in Barcelona, Spain
    32nd Annual Deutsche Bank Media, Internet & Telecom Conference, taking place on Monday, March 11 at The Breakers Hotel in Palm Beach, FL.
  • Management will host investor meetings throughout the day
    36th Annual ROTH Conference, taking place on Monday, March 18 at The Ritz-Carlton Laguna Niguel in Dana Point, CA.
  • Management will host investor meetings throughout the day
    SATELLITE 2024, taking place on Tuesday, March 19 to Wednesday, March 20 at the Walter E. Washington Convention Center in Washington, DC

Quantic Electronics to Exhibit at the SATELLITE 2024 Conference and Exhibition

Retrieved on: 
Wednesday, March 6, 2024

EAST PROVIDENCE, R.I., March 6, 2024 /PRNewswire/ -- Quantic® Electronics ("Quantic"), today announced that it will exhibit at the SATELLITE 2024 Conference and Exhibition, hosted in Washington, D.C. at the Walter E. Washington Convention Center, March 19th-21st. Representatives from Quantic and its businesses Quantic™ ECI, Quantic™ Ohmega Ticer, Quantic™ PMI (Planar Monolithics Inc.) and Quantic™  TRM will be available at Booth #1438 to showcase our RF and microwave technology solutions, including resistors, magnetics, and custom and passive components.

Key Points: 
  • EAST PROVIDENCE, R.I., March 6, 2024 /PRNewswire/ -- Quantic® Electronics ("Quantic"), today announced that it will exhibit at the SATELLITE 2024 Conference and Exhibition , hosted in Washington, D.C. at the Walter E. Washington Convention Center, March 19th-21st.
  • Representatives from Quantic and its businesses Quantic™ ECI , Quantic™ Ohmega Ticer, Quantic™ PMI (Planar Monolithics Inc.) and Quantic™  TRM will be available at Booth #1438 to showcase our RF and microwave technology solutions, including resistors, magnetics, and custom and passive components.
  • Quantic Electronics to exhibit at the SATELLITE show, Booth #1438.
  • The SATELLITE Conference and Exhibition is an annual event focused on connecting and uniting the satellite industry, with participation across the satellite, space, and commercial communities.

Ash Carter Exchange on Innovation and National Security Convenes Prominent Public-Sector Leaders, Futurists, Technologists, Researchers, and Entrepreneurs

Retrieved on: 
Tuesday, March 5, 2024

The Ash Carter Exchange, an innovation and national security forum organized jointly by SCSP and Mrs. Stephanie Carter, brings together pioneers and champions of innovation from the government, private sector, and scientific community to examine how to advance collaboration in pursuit of national security.

Key Points: 
  • The Ash Carter Exchange, an innovation and national security forum organized jointly by SCSP and Mrs. Stephanie Carter, brings together pioneers and champions of innovation from the government, private sector, and scientific community to examine how to advance collaboration in pursuit of national security.
  • The event honors and advances the legacy of former Secretary of Defense, Dr. Ash Carter, whose recognition of technology's role in national security continues to inspire preparedness for tomorrow's challenges.
  • "Alongside the AI Expo, we look forward to exchanging ideas, forging strategic collaborations, and ultimately, solidifying the nation's place as a leader in emerging technology and national security."
  • Current list of confirmed speakers of this year's Ash Carter Exchange includes:
    Dr. Meghan O'Sullivan, Director of the Belfer Center, Harvard University
    For more information on SCSP, the Ash Carter Exchange on Innovation and National Security, and the AI Expo for National Competitiveness, please visit https://www.scsp.ai .

Datenna, Groq, and Lockheed Martin Join Roster of Sponsors for Upcoming AI Expo for National Competitiveness

Retrieved on: 
Wednesday, February 28, 2024

ARLINGTON, Va., Feb. 28, 2024 /PRNewswire/ -- The Special Competitive Studies Project (SCSP), a non-partisan, non-profit project dedicated to strengthening America's long-term competitiveness in artificial intelligence (AI), announced today three additional sponsors of the AI Expo for National Competitiveness happening on May 7-8 at the Walter E. Convention Center in Washington, D.C. At the "Disruptor" sponsorship level, SCSP welcomes Datenna, an Open-source intelligence (OSINT) software company that equips governments with actionable insights into China's techno-economic landscape. SCSP is also announcing two "Maverick"-level sponsors: Groq®, a generative AI solutions company and creator of the Language Processing Unit (LPU™), and Lockheed Martin (NYSE: LMT), a global defense technology company driving innovation and advancing scientific discovery by providing the all-domain mission solutions and vision needed to accelerate the delivery of transformative technologies.

Key Points: 
  • "These three sponsors exemplify what the AI Expo intends to bring into focus," said SCSP CEO and President Ylli Bajraktari.
  • "They are representative of the intersection of AI, defense, and national security policy – a key focus of SCSP's work and will further the AI Expo's dialogue on U.S. leadership in emerging technologies.
  • "Our sponsorship of the AI Expo for National Competitiveness shows our commitment to empowering governments with unmatched insight and knowledge for superior decision-making."
  • For more information on SCSP, the AI Expo for National Competitiveness, and the Ash Carter Exchange please visit https://www.scsp.ai .

Palantir Technologies Partners with SCSP's AI Expo on National Competitiveness

Retrieved on: 
Tuesday, February 13, 2024

"Palantir is a demonstrated leader in AI, and their support for the expo we're organizing is phenomenal.

Key Points: 
  • "Palantir is a demonstrated leader in AI, and their support for the expo we're organizing is phenomenal.
  • "Forums like the SCSP AI Expo are key to fostering the robust and innovative ecosystem needed to maintain our national security and competitive edge," said Shyam Sankar, CTO at Palantir.
  • SCSP will also host its second annual Ash Carter Exchange on Innovation and National Security with Mrs. Stephanie Carter, which will be co-located with the AI Expo.
  • For more information on SCSP, the AI Expo for National Competitiveness, and the Ash Carter Exchange please visit https://www.scsp.ai .

NYU Langone Orthopedic Surgeons Present Latest Clinical Findings & Research at AAOS 2024

Retrieved on: 
Monday, February 12, 2024

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Experts from NYU Langone Orthopedics will present their latest clinical findings and research discoveries at the American Academy of Orthopaedic Surgeons' (AAOS) 2024 Annual Meeting, February 12-16, in San Francisco.

Key Points: 
  • SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Experts from NYU Langone Orthopedics will present their latest clinical findings and research discoveries at the American Academy of Orthopaedic Surgeons' (AAOS) 2024 Annual Meeting, February 12-16, in San Francisco.
  • "This year's impressive group of presentations at the nation's premier orthopedic meeting is a testament to why NYU Langone Orthopedics endeavors to always deliver world-class care to our patients."
  • At this year's meeting, faculty of NYU Langone Orthopedics will present 39 posters, 31 e-posters, 34 papers, 31 videos, and 21 symposia, courses, specialty programs, and special sessions.
  • Surgeons at NYU Langone endeavored to determine short-term patient outcomes using these minimally invasive, precision-based technologies.